Merck said topline Phase 3 results show an injectable version of Keytruda met the main goal of non-inferiority compared to the intravenously infused formulation that is the pharma giant’s top-selling product. Injectable Keytruda could help Merck compete against coming competition from biosimilars.
Boehringer’s adalimumab-adbm is being offered on GoodRx’s platform for $550 per two-pack, a 92% discount from the Humira list price, according to the companies.
Across the nation, state-based health insurance exchanges are searching for ways to better serve their communities while making enrollment easier, more personal, and more accessible for everyone.
FDA draft guidance eliminates the requirement that biosimilars produce clinical data to show they are interchangeable with their reference drugs. Some lawmakers have said these so-called switching studies add time and expense to the development of biosimilars, delaying them from reaching patients.
Sandoz drugs Jubbonti and Wyost are approved for use in all indications covered by the Amgen products, Prolia and Xgeva. But no launch date is planned yet, due to ongoing patent litigation between the two companies.
Insulin prices have long been a pain point for diabetics. The big three insulin manufacturers have cut prices across their product lineups, but potential competition from other biosimilar insulins is still in earlier stages of development.
While Covid-19 has had a significant impact on drug spending, IQVIA projects that its effect will moderate in coming years. IQVIA’s new report on U.S. medicines spending projects that immunology, oncology, and neurology will continue to drive the growth in drug spending.
In a landscape where complexity has long been the norm, the power of one lies not just in unification, but in intelligence and automation.
The FDA has approved the first biosimilar that references the blockbuster Roche drug Lucentis. The Biogen and Samsung BioLogics joint venture that developed the biologic product have approval to treat three eye conditions that lead to vision loss.
Legislators threaten to ban settlements where branded companies "pay" generics makers to "delay" market entry, while drugmakers say the current framework balances competition and innovation. Who will prevail?
Johnson & Johnson is hoping that its blockbuster drug will be protected through its network with large healthcare systems when biosimilar competition arrives to U.S. shores.
Also, Minneapolis nurses with five hospitals go on strike and Hologic became the third company to develop a blood test for the Zika Virus that U.S. regulators have greelighted for emergency use.
In a recent interview, Esperion president and CEO, Sheldon Koenig talks about the reality of statin intolerance and his company’s expansion into new diseases
It's clear that more biosimilars are close to completion and marketing than not; 12 are in preclinical development, whereas 23 are almost ready to be filed.